By Carlo Martuscelli
AstraZeneca PLC (AZN.LN) on Friday announced negative results from a phase 3 clinical trial of its cancer drug Imfinzi as a treatment for recurrent or metastatic head and neck squamous cell carcinoma.
The company said neither Imfinzi alone, nor Imfinzi plus add-on therapy tremelimumab, increased overall survival for treated patients when compared with standard-of-care chemotherapy, missing the primary objective in the Eagle trial. The patients enrolled in study had previously had their disease advance following platinum-based chemotherapy.
The Anglo-Swedish pharmaceutical said that while the results were disappointing, it remained committed to evaluating Imfinzi as a potential medicine for patients with head and neck cancer.
Write to Carlo Martuscelli at firstname.lastname@example.org